...
首页> 外文期刊>Neurogastroenterology and motility >The effect of mirtazapine on gastric accommodation, gastric sensitivity to distention, and nutrient tolerance in healthy subjects
【24h】

The effect of mirtazapine on gastric accommodation, gastric sensitivity to distention, and nutrient tolerance in healthy subjects

机译:Mirtazapine对胃容纳,胃敏感性的胃敏感,以及健康受试者的养分耐受性的影响

获取原文
获取原文并翻译 | 示例
           

摘要

Abstract Background Disturbances of gastric motor function of functional dyspepsia ( FD ) have been implicated in the pathogenesis of the symptoms, and hence, motility modifying agents are considered for its treatment. Mirtazapine was recently shown to improve symptoms and increase nutrient tolerance in FD patients with weight loss. We aim to evaluate the effect of mirtazapine on gastric sensorimotor function in healthy volunteers ( HV ). Methods Thirty‐one HV underwent an intragastric pressure ( IGP ) and barostat measurements on separate days before and after 3?weeks of placebo or mirtazapine (15?mg). Gastric compliance, sensitivity and accommodation ( GA ) measured by the barostat. GA was quantitated as the difference (delta) in intra‐balloon volume before and after ingestion of 200?mL of a nutrient drink ( ND ). GA measured by IGP was quantitated as the drop of IGP from baseline during the intragastric infusion of ND until maximal satiation. Key Results Mirtazapine significantly increased the bodyweight of subjects (67.8±3.7 to 69.1±3.7?kg; P =.01). Barostat results showed no effect on gastric compliance, sensitivity, and GA . Nutrient tolerance was not affected after treatment (1170±129.4 vs 1104±133.6?kcal; P =.4), and mirtazapine was associated with lower symptom ratings. The IGP drop during meal ingestion was significantly suppressed (area under the curve: ?43.3±4.5?mm Hg vs ?28.9±3.1?mm Hg; P =.005). Conclusions & Inferences In HV s, the occurrence of weight gain and decreased meal‐induced symptoms in spite of a suppressed meal‐induced IGP drop, point towards a central mode of action. Mirtazapine does not display changes in gastric sensorimotor function that could explain its beneficial effects on symptoms and nutrient tolerance in FD .
机译:摘要功能性消化症(FD)胃运动功能的背景涉及症状的发病机制,因此考虑了运动改性剂的治疗。最近显示Mirtazapine,以改善症状,并增加FD患者减肥患者的养分耐受性。我们的目标是评估Mirtazapine对健康志愿者(HV)的胃感子功能的影响。方法三十一HV在3〜30次安慰剂或Mirtazapine(15μmg)之前和之后的单独日期进行胃内压力(IGP)和Barostat测量。 Barostat测量的胃合规性,敏感度和容纳(GA)。在摄入200μl营养饮料(ND)之前和之后,将GA定量为球囊体积中的差异(Delta)。通过IGP测量的GA被定量为ND胃内输注过程中的基线的IGP滴,直到最大饱结。关键结果Mirtazapine显着增加了受试者体重(67.8±3.7至69.1±3.7?kg; p = .01)。 Barostat结果对胃依从性,敏感性和GA没有影响。治疗后营养耐受性不受影响(1170±129.4 vs1104±133.6?kcal; p = .4),Mirzapine与症状评级较低有关。在膳食中摄入期间的IGP下降显着抑制(曲线下的面积:?43.3±4.5?mm Hg vsΔ28.9±3.1?mm hg; p = .005)。结论& HV S中的推论,重量增长和减少的膳食诱导的症状,尽管抑制了额外的膳食诱导的IGP下降,指向中央行动模式。 Mirtazapine没有显示胃感型功能的变化,可以解释其对FD中症状和营养耐受性的有益影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号